# *In Vitro* and *In Vivo* Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

Paul E. Hughes, Karen Rex, Sean Caenepeel, Yajing Yang, Yihong Zhang, Martin A. Broome, Hue T. Kha, Teresa L Burgess, Benny Amore, Paula J. Kaplan-Lefko, Jodi Moriguchi, Jonathan Werner, Michael A. Damore, Daniel Baker, Deborah M. Choquette, Jean-Christophe Harmange, Robert Radinsky, Richard Kendall, Isabelle Dussault, and Angela Coxon

Amgen Inc.,\* Thousand Oaks, CA

Running title: AMG 337 inhibits growth of MET-dependent cancer models

Keywords: AMG 337, MET, small-molecule, xenograft; CB02 cell growth/signaling pathways: protein tyrosine kinases; CB01 cell cycle: phosphorylation and proteolysis in cell cycle control

Financial support: This study was supported by Amgen Inc.

Corresponding author:

Angela Coxon, DPhil

Amgen Inc.

One Amgen Center Drive, Mail stop: 15-2-A

Thousand Oaks, CA 91320

Phone: 1-805-447-0130

Fax: 1-805-375-8524

Email: acoxon@amgen.com

Conflicts of Interest: All authors are current or former employees of Amgen Inc. and owned stock in Amgen Inc. at the time this work was conducted.

\*All authors were employees of Amgen Inc. at the time this work was conducted.

# Supplementary Table S1. Enzymatic and cellular potency of Amgen Compound 5

|  |  |  |
| --- | --- | --- |
| ***MET* (Enzymatic Activity)** | **IC50 (nM)** |  |
| Wild-type | 2 |
| HGF-stimulated pMET (PC3 cells) | 8 |

HGF=hepatocyte growth factor.